Skip to main content

Table 7 Relation between genotypes and clinicopathological data among HCC patients

From: Association between miR-196a2 polymorphism and the development of hepatocellular carcinoma in the Egyptian population

Studied variable

Genotype

Kruskal–Wallis test

P value

CC

N = 21

TC

N = 42

TT

N = 17

AST (U/L)

 Min-max

12.0–302.0

21.0-540.0

14.00-258.00

0.38

0.82

X ± SD

83.96 ± 70.88

158.04 ± 269.99

90.56 ± 78.90

 Median

67.50

93.00

66.00

ALT (U/L)

 Min-max

11.0–292.00

12.0–379.0

11.0–205.0

1.10

0.57

X ± SD

80.14 ± 61.68

83.57 ± 83.45

67.82 ± 49.62

 Median

64.000000

59.00

53.0

ALB (g/dL)

 Min-max

2.0–4.0

2.0–4.0

2.0–4.0

1.25

0.53

X ± SD

2.73 ± .70

2.54 ± .58

2.61 ± .67

 Median

3.0

3.00

2.0

BT (mg/dL)

 Min-max

1.0–16.0

1.0–20.0

1.0–9.0

0.05

0.97

X ± SD

4.03 ± 3.96

3.66 ± 3.54

3.36 ± 2.43

Median

2.0

3.00

3.00

BD (mg/dL)

 Min-max

1.0–16.0

1.0–15.00

1.0–8.0

0.94

0.62

X ± SD

3.58 ± 4.46

2.55 ± 2.92

3.03 ± 2.56

 Median

1.00

1.0

2.0

AFP (ng/mL)

 Min-max

12-5200

11-20,949

6-19,007

3.35

0.18

X ± SD

1586.48 ± 1513.68

1801.07 ± 4254.21

2052.71 ± 4561.92

 Median

615.00

420.00

680.00

Focal lesion

 Min-max

1.50–9.00

1.50–8.00

2.00–11.00

1.5

0.22

X ± SD

4.81 ± 2.10

3.99 ± 1.72

4.75 ± 2.07

 Median

5.00

4.0

4.50

PT. conc

 Min-max

19-96

20-102

29–89

0.73

0.69

X ± SD

56.26 ± 18.66

59.40 ± 16.54

58.43 ± 16.53

 Median

55.00

63.00

57.00

PT.INR

 Min-max

1.03–2.71

.95–3.59

1.08–2.40

0.61

0.73

X ± SD

1.54 ± .45

1.45 ± .45

1.47 ± .37

 Median

1.4150

1.3300

1.45